Dr. Tedros Adhanom Ghebreyesus, director of the World Health Organisation WHO, has said the initial clinical trial results from the United Kingdom (UK) that show that dexamethasone can be lifesaving for treating patients, who are critically ill with COVID-19 is great news and welcome development.
He made this assertion on Wednesday in a statement.
He, however, clarified that an in-depth analysis of the intervention will be carried out, before issuing clinical guidance on how and when the drug should be used.
Ghebreyesus said: “This is a welcome news. I congratulate the Government of the United Kingdom, University of Oxford, the research groups, hospitals, patients, and families who have collectively contributed to this lifesaving breakthrough.
“WHO looks forward to learning more about the dexamethasone study. This is the first treatment to be shown to reduce mortality in severely ill patients with COVID-19 requiring oxygen or ventilator support.
“There are many ongoing clinical trials for COVID-19, including the Solidarity Trial launched by WHO and partners. It is hoped that more treatments under clinical evaluation will result in improving patient outcomes and save lives.”
"I want to thank the 🇬🇧 government, the @UniofOxford, and the many hospitals, researchers, patients and families who have contributed to this scientific breakthrough"-@DrTedros #COVID19 #dexamethasonehttps://t.co/hmay04nIPv
— World Health Organization (WHO) (@WHO) June 17, 2020